Cellantra Files Patent Application Covering G059, a Proprietary Surface-Targeting Ligand for Precision Gene Delivery
CellantraTechTech Files Patent Application Covering G059, a Proprietary Surface-Targeting Ligand for Precision Gene Delivery
Cellantra Announces Discovery of Novel MAGE-C1-Targeting TCR Candidate for Cancer Immunotherapy
CellantraTechTech Announces Discovery of Novel MAGE-C1-Targeting TCR Candidate for Cancer Immunotherapy
CellentraTech Announces Discovery of Novel KRAS G12D / HLA-C08 TCR Candidate for Precision Cancer Immunotherapy
CellentraTech Announces Discovery of Novel KRAS G12D / HLA-C08 TCR Candidate for Precision Cancer Immunotherapy
CellantraTech Signs Strategic Agreement with NVIDIA to Accelerate AI-Driven Cancer Drug Discovery and Gene Therapy Development
CellantraTech Signs Strategic Agreement with NVIDIA to Accelerate AI-Driven Cancer Drug Discovery and Gene Therapy Development
CellantraTech Signs Memorandum with Moderna to Advance mRNA Manufacturing Capabilities
CellantraTech Signs Memorandum with Moderna to Advance mRNA Manufacturing Capabilities
CellantraTech Signs Memorandum with Moderna to Advance mRNA Manufacturing Capabilities Read More »
CellentraTech Files Patent Application Covering W2993, Advancing Intellectual Property Strategy for Lead KRAS G12D Program
CellentraTech Files Patent Application Covering W2993, Advancing Intellectual Property Strategy for Lead KRAS G12D Program
